Vol. 1 No. 11 (2021)
Reimbursement Reviews

Givosiran (Givlaari)

Published November 15, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses givosiran (Givlaari), 189 mg/mL, solution for subcutaneous injection.
  • Indication: For the treatment of acute hepatic porphyria in adults.